Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec 13;226(12):2054-2063.
doi: 10.1093/infdis/jiac189.

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults

James Baber  1 , Mark Arya  2 , Yuben Moodley  3 , Anna Jaques  1 , Qin Jiang  4 , Kena A Swanson  4 , David Cooper  4 , Mohan S Maddur  4 , Jakob Loschko  4 , Alejandra Gurtman  4 , Kathrin U Jansen  4 , William C Gruber  4 , Philip R Dormitzer  4 , Beate Schmoele-Thoma  5
Affiliations
Clinical Trial

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults

James Baber et al. J Infect Dis. .

Abstract

Background: Respiratory syncytial virus (RSV) is an important cause of disease in older adults. We evaluated the safety and immunogenicity of a stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate with/without adjuvant in adults aged 65-85 years.

Methods: Primary cohort participants were equally randomized to 1 of 7 RSVpreF formulations: 60 µg with either Al(OH)3 or CpG/Al(OH)3, 120 µg with either Al(OH)3 or CpG/Al(OH)3, 240 µg with either Al(OH)3 or CpG/Al(OH)3, 240 µg unadjuvanted, or placebo, administered concomitantly with high-dose seasonal inactivated influenza vaccine (SIIV). Participants in the month 0,2 cohort were randomized to RSVpreF 240 µg with CpG/Al(OH)3 or placebo, administered at months 0 and 2.

Results: All RSVpreF vaccine candidates elicited robust and persistent serum neutralizing responses when administered alone or with SIIV. There was no notable difference in neutralizing response between the formulations, including those containing CpG. In the month 0,2 cohort, there was no booster effect of dose 2. SIIV responses were similar or slightly lower with concomitant administration of RSVpreF. Most systemic and local reactions were mild and more frequent after RSVpreF than placebo.

Conclusions: RSVpreF formulations were well tolerated and elicited robust neutralizing responses in older adults; however, CpG/Al(OH)3 did not further enhance responses. Clinical Trials Registration. NCT03572062.

Keywords: RSV; prefusion F subunit; respiratory syncytial virus; vaccine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . J. B., A. J., Q. J., K. S., D. C., M. M., J. L., A. G., K. J., W. G., P. D., and B. S.-T. are employees of Pfizer Inc and may hold Pfizer Inc stock or stock options. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Participant disposition in the (A) primary cohort and (B) month 0,2 cohort. Abbreviations: AE, adverse event; PBMC, peripheral blood mononuclear cell; RSVpreF 60, 120, and 240, stabilized respiratory syncytial virus prefusion F subunit vaccine (dose levels 60, 120, and 240 µg, respectively).
Figure 2.
Figure 2.
Percentages of participants reporting local reactions within 14 days after vaccination in the (A) primary cohort and (B) month 0,2 cohort. Error bars are 95% confidence intervals. Abbreviations: A, Al(OH)3; CpG/A, CpG/Al(OH)3; F 60, 120, and 240, stabilized respiratory syncytial virus prefusion F subunit vaccine (dose levels 60, 120, and 240 µg, respectively).
Figure 3.
Figure 3.
Percentages of participants reporting systemic reactions within 14 days after vaccination in the (A) primary cohort and (B) month 0,2 cohort. aMild, moderate, severe, and grade 4 fever defined as temperatures of 38.0–38.4°C, 38.5–38.9°C, 39.0–40.0°C, and >40.0°C, respectively. There were no grade 4 reactions or events. No cases of vomiting were reported. Error bars are 95% confidence intervals. Abbreviations: A, Al(OH)3; CpG/A, CpG/Al(OH)3; F 60, 120, and 240, stabilized respiratory syncytial virus prefusion F subunit vaccine (dose level 60, 120, and 240 µg, respectively).
Figure 4.
Figure 4.
RSV A and RSV B neutralizing GMTs at month 1 (A and C) and through month 12 (B and D) in the primary cohort (A and B) and month 0,2 cohort (C and D). Error bars are 95% confidence intervals. Abbreviations: A, Al(OH)3; CI, confidence interval; CpG/A, CpG/Al(OH)3; F 60, 120, and 240, stabilized respiratory syncytial virus prefusion F subunit vaccine (dose levels 60, 120, and 240 µg, respectively); GMFR, geometric mean fold rise; GMT, geometric mean titer; RSV, respiratory syncytial virus.
See this image and copyright information in PMC

References

    1. Hall CB, Weinberg GA, Blumkin AK, et al. . Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013; 132:e341–8. - PubMed
    1. Sundaram ME, Meece JK, Sifakis F, Gasser RA Jr, Belongia EA. Medically attended respiratory syncytial virus infections in adults aged ≥ 50 years: clinical characteristics and outcomes. Clin Infect Dis 2014; 58:342–9. - PMC - PubMed
    1. Wyffels V, Kariburyo F, Gavart S, Fleischhackl R, Yuce H. A real-world analysis of patient characteristics and predictors of hospitalization among US Medicare beneficiaries with respiratory syncytial virus infection. Adv Ther 2020; 37:1203–17. - PMC - PubMed
    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749–59. - PubMed
    1. Centers for Disease Control and Prevention . Respiratory syncytial virus infection (RSV). Trends and surveillance. https://www.cdc.gov/rsv/research/us-surveillance.html. Accessed 02 November 2020.

Publication types

Associated data